Anti-Human PRAME-Anti-Human PRAME代理/参数/厂家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

产品中心

当前位置：首页 > 产品中心 > 免疫学产品 > 一抗

背景资料: PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or „preferentially expressed antigen in melanoma”, was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein),

其他: ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。